Blog
RSS FeedPosted by Michael Wonder on 16 Apr 2024
Norgine submits marketing authorisation application via Project Orbis for eflornithine (difluoromethylornithine) in high-risk neuroblastoma
15 April 2024 - Norgine today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine ...
Posted by Michael Wonder on 11 Mar 2023
COVID-19 vaccine safety report (9 March 2023)
9 March 2023 - To 5 March 2023, over 44 million doses have been administered in Australia, as well as about ...
Posted by Michael Wonder on 07 Nov 2022
The Australian Government is committed to ensuring the safety of those at risk of monkeypox and has been working closely with states, territories and key stakeholders to ensure a coordinated national response
7 November 2022 - The Australian Government is committed to ensuring the safety of those at risk of monkeypox and ...
Posted by Michael Wonder on 23 Feb 2021
TGA bans Pfizer, AstraZeneca brand mentions in COVID-19 vaccine advertising
24 February 2021 - Pharmacies, GPs and healthcare organisations will be banned from displaying advertisements identifying whether they are using ...
Posted by Michael Wonder on 21 Nov 2019
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukaemia
21 November 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, ...
Posted by Michael Wonder on 10 Jul 2017
CSL to fight patent infringement claim from US based Bioverativ
10 July 2017 - Australian vaccines and blood products developer CSL says it will vigorously fight a patent infringement claim ...
Posted by Michael Wonder on 31 Jan 2017
Trump health pick Tom Price pressed over purchase of shares in ASX-listed biotech Innate
31 January 2017 - US Republican politician Tom Price got a privileged offer to buy an Australian biomedical stock at ...